Results 81 to 90 of about 1,682,375 (348)

Five‐Year Disease Progression in Synuclein Seeding Positive Sporadic Parkinson's Disease

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective To provide a comprehensive description of disease progression in synuclein seeding assay (SAA) positive sporadic Parkinson Disease participants, using Neuronal Synuclein Disease integrated biological and functional impairment staging framework.
Paulina Gonzalez‐Latapi, Caroline Gochanour, Seung Ho Choi, Hyunkeun Cho, Chelsea Caspell‐Garcia, Christopher Coffey, Michael Brumm, David‐Erick Lafontant, Yuge Xiao, Thomas Tropea, John Seibyl, Caroline Tanner, Charles S. Venuto, Karl Kieburtz, Lana M. Chahine, Kathleen L. Poston, Andrew Siderowf, Kenneth Marek, Tanya Simuni, The Parkinson's Progression Markers Initiative   +19 more
wiley   +1 more source

Residual symptoms and functioning in depression, does the type of residual symptom matter? A post-hoc analysis

BMC Psychiatry, 2013
Background The degrees to which residual symptoms in major depressive disorder (MDD) adversely affect patient functioning is not known. This post-hoc analysis explored the association between different residual symptoms and patient functioning.
Romera Irene, Pérez Víctor, Ciudad Antonio, Caballero Luis, Roca Miguel, Polavieja Pepa, Gilaberte Inmaculada   +6 more
doaj   +1 more source

TBK1‐Associated Primary Lateral Sclerosis Followed by Right Temporal Variant Frontotemporal Dementia

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT We report a 58‐year‐old woman with a novel splice‐site variant in the TANK‐binding kinase 1 (TBK1:c.993–2A>C p.Ala332TyrfsTer39) who sequentially developed primary lateral sclerosis (PLS) followed by right temporal variant frontotemporal dementia (rtvFTD). Neuroimaging demonstrated right anterior temporal atrophy before cognitive symptoms, and
Tomoyasu Matsubara, Naoki Kihara, Satoko Miyatake, Koji Fujita, Konoka Tachibana, Ryosuke Miyamoto, Hiroki Yamazaki, Yusuke Osaki, Nazere Keyoumu, Yuki Kuwano, Nobutoshi Morimoto, Suzuran Saito, Eriko Koshimizu, Yoichi Otomi, Kenji Ishibashi, Masafumi Harada, Naomichi Matsumoto, Hiroyuki Morino, Yuishin Izumi   +18 more
wiley   +1 more source

Augmentation strategies for inadequate response in major depressive disorder

Psychiatry and Clinical Psychopharmacology, 2021
A substantial number of patient, treated for major depressive disorder (MDD), fail to achieve an adequate response to antidepressant medication. At least 50% of those who begin treatment with antidepressant monotherapy fail to respond and 30% of those ...
Nesrin Dilbaz, Serçin Yalçın Çavuş
doaj  

The reported use and effectiveness of Hypericum (St John’s wort) on affective symptoms in a depression self-help group [PDF]

, 2002
A recent meta-analysis suggested that Hypericum perforatum (St John’s wort) is an effective treatment for mild to moderate depression and may have a superior side-effect profile to some antidepressant drugs.
Baldwin, D.S., Dyson, R., Jenkins, G., Mayers, A.G., Tiernan, A.   +4 more
core   +1 more source

Efficacy of Intermittent Theta‐Burst Stimulation for Prolonged Disorders of Consciousness: A Prospective, Randomized, Controlled Trial

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Emerging evidence suggests that low‐frequency neural oscillations are dynamically regulated by consciousness levels, with the recovery of low cortical activity potentially serving as a neurophysiological substrate for conscious emergence. Targeted enhancement of these low‐frequency rhythms in patients with disorders of consciousness
Chuan Xu, Jun Hu, Qianqian Wu, Min Wu, Yamei Yu, Hangcheng Li, Jian Gao, Jingqi Li, Nai Ding, Jie Yu, Benyan Luo   +10 more
wiley   +1 more source

Efficacy of Botox versus Placebo for Treatment of Patients with Major Depression

Iranian Journal of Public Health, 2017
Background: Treatment of major depression is crucial to decrease the burden of disease. Hence, in this study, the efficacy of Botox was compared with placebo for treatment of patients with major depression. Methods: In this randomized clinical trial, 28
Abbas ZAMANIAN, Atefeh GHANBARI JOLFAEI, Golnaz MEHRAN, Zahra AZIZIAN   +3 more
doaj  

The Efficacy of Moclobemide in Treatment of Major Depression

Psychiatry and Clinical Psychopharmacology, 2021
The effectiveness and the tolerence of moclobemde -one of the reversible inhibitors of MAO-A were assessed in an open clinical trial on 19 inpatients with major depression according to DSM.III and with a score of 16 or more on Hamilton Rating Scale of ...
Ayhan EĞRİLMEZ, Ömer AYDEMİR, Cumhur ÖNAL, Savaş KÜLTÜR   +3 more
doaj  

Cognitive, behavioral, and autonomic correlates of mind wandering and perseverative cognition in major depression [PDF]

, 2014
Autonomic dysregulation has been hypothesized to play a role in the relationships between psychopathology and cardiovascular risk. An important transdiagnostic factor that has been associated with autonomic dysfunction is perseverative cognition (PC ...
Cristina eOttaviani, David eShapiro, Ian eCook, Leila eShahabi, Michelle eAbrams, Mika eTarvainen, Mika eTarvainen   +6 more
core   +4 more sources

Posterior Cortical Atrophy in the Asia‐Pacific: A Report From the PCA Asian Workgroup

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Posterior Cortical Atrophy (PCA) is a distinct dementia syndrome primarily affecting spatial abilities and visual processing. It is associated with degeneration in the posterior part of the brain. PCA is subclassified into PCA‐pure and PCA‐plus syndromes based on consensus criteria.
Yuttachai Likitjaroen, Ya‐Ting Chang, Levinia Lim, Pai‐Yi Chiu, Jung‐Lung Hsu, SangYun Kim, Wataru Narita, Na Young Ryoo, Kyoko Suzuki, Nagaendran Kandiah, Sebastian Crutch, Ming‐Chyi Pai   +11 more
wiley   +1 more source